Hazem Assi

3.7k total citations · 1 hit paper
103 papers, 2.5k citations indexed

About

Hazem Assi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Hazem Assi has authored 103 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 32 papers in Cancer Research. Recurrent topics in Hazem Assi's work include Breast Cancer Treatment Studies (17 papers), Glioma Diagnosis and Treatment (13 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Hazem Assi is often cited by papers focused on Breast Cancer Treatment Studies (17 papers), Glioma Diagnosis and Treatment (13 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Hazem Assi collaborates with scholars based in Lebanon, United States and Canada. Hazem Assi's co-authors include Maroun Bou Zerdan, Sabine Allam, Gracia Fahed, Morgan Bou Zerdan, Youssef Bouferraa, Fadi Saadeh, Rami Mahfouz, David M. Berman, Omid Hamid and Jeffrey S. Weber and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Hazem Assi

91 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Metabolic Syndrome: Updates on Pathophysiology and Management in 2021

2022 827 citations Maroun Bou Zerdan, Hazem Assi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hazem Assi Lebanon	19	1.1k	552	486	408	364	103	2.5k
Clara Chen United States	24	832 0.8×	604 1.1×	504 1.0×	401 1.0×	235 0.6×	101	2.6k
Chen Yuan China	31	851 0.8×	930 1.7×	252 0.5×	519 1.3×	272 0.7×	121	3.3k
Jie Cai China	35	1.2k 1.1×	813 1.5×	268 0.6×	696 1.7×	260 0.7×	163	3.8k
Soo Jung Park South Korea	34	868 0.8×	858 1.6×	475 1.0×	555 1.4×	764 2.1×	201	3.6k
Jialiang Wang China	15	737 0.7×	1.0k 1.9×	294 0.6×	242 0.6×	332 0.9×	34	2.7k
Holger Rumpold Austria	28	862 0.8×	796 1.4×	997 2.1×	337 0.8×	668 1.8×	84	3.3k
Jan DʼHaese Germany	32	1.3k 1.2×	929 1.7×	444 0.9×	1.0k 2.5×	369 1.0×	111	3.8k
Ying Xiong China	29	726 0.7×	821 1.5×	396 0.8×	578 1.4×	369 1.0×	134	2.3k
Xinyu Qin China	33	1.3k 1.2×	887 1.6×	505 1.0×	1.2k 3.0×	261 0.7×	131	4.0k
Lijian Tao China	30	304 0.3×	1.2k 2.1×	454 0.9×	517 1.3×	414 1.1×	148	3.1k

Countries citing papers authored by Hazem Assi

Since Specialization

Citations

This map shows the geographic impact of Hazem Assi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hazem Assi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hazem Assi more than expected).

Fields of papers citing papers by Hazem Assi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hazem Assi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hazem Assi. The network helps show where Hazem Assi may publish in the future.

Co-authorship network of co-authors of Hazem Assi

This figure shows the co-authorship network connecting the top 25 collaborators of Hazem Assi. A scholar is included among the top collaborators of Hazem Assi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hazem Assi. Hazem Assi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghezzawi, Malak, Vahé Panossian, Anthony Haddad, et al.. (2025). Patterns of response of breast cancer after neoadjuvant chemotherapy according to molecular subtype. Frontiers in Oncology. 15. 1670594–1670594.

Ghezzawi, Malak, et al.. (2025). Patterns of Management of Positive Sentinel Lymph Nodes in Breast Cancer Patients After the American College of Surgeons Oncology Group Z0011 Trial: A Retrospective Study. Cancers. 17(22). 3621–3621.

Kamel, Rasha, Hazem Assi, Mohamad Khalifeh, et al.. (2025). Impact of the COVID-19 Pandemic on Breast Cancer Patient Care: Results From a Tertiary Care Center in Lebanon. JCO Global Oncology. 11(11). e2400275–e2400275.

Sbaity, Eman, Amine Slim, Ali Tarhini, et al.. (2025). Fertility preservation in female cancer patients: assessing awareness, attitudes, concerns, experiences, and the role of counseling in quality of life. Journal of Assisted Reproduction and Genetics. 42(5). 1401–1414.

Assi, Hazem, et al.. (2024). Liquid biopsy in brain tumors: Potential for impactful clinical applications. Human Gene. 42. 201333–201333. 1 indexed citations

Assi, Hazem, et al.. (2024). Enhanced Pancreatitis Detection: FAPI PET/CT Emerging Utility in Patient with Pancreatic Mass. Diagnostics. 14(15). 1622–1622.

Mohty, Razan, et al.. (2024). Outcomes of Cancer Patients Affected by COVID‐19 in Different Settings: A Retrospective Study in Lebanon. Cancer Reports. 7(11). e70045–e70045.

Hassan, Mohd Ali, et al.. (2024). Prevalence of depression and anxiety among newly diagnosed cancer patients: a single centre experience in the Middle East. ecancermedicalscience. 18. 1690–1690. 2 indexed citations

Assi, Hazem, et al.. (2023). Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC). Oncotarget. 14(1). 517–525. 4 indexed citations

10.

Tfayli, Arafat, Hazem Assi, Ghina Berjawi, et al.. (2023). Prone versus Supine FDG PET/CT in the Staging of Breast Cancer. Diagnostics. 13(3). 367–367.

11.

Saghir, Nagi S. El, Lana Khalil, Maya Charafeddine, et al.. (2023). Improved Survival of Young Patients With Breast Cancer 40 Years and Younger at Diagnosis. JCO Global Oncology. 9(9). e2200354–e2200354. 8 indexed citations

12.

Iratni, Rabah, et al.. (2023). Immunotherapy and immunoevasion of colorectal cancer. Drug Discovery Today. 28(9). 103669–103669. 44 indexed citations

13.

Panossian, Vahé, et al.. (2023). Performance and oncologic safety of sentinel lymph node biopsy after neoadjuvant chemotherapy: Results from a tertiary care center in Lebanon. Cancer Medicine. 13(1). e6868–e6868. 1 indexed citations

14.

Assi, Hazem, et al.. (2023). Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer. Frontiers in Oncology. 13. 1181375–1181375. 1 indexed citations

15.

Kast, Richard E., Alex Alfieri, Hazem Assi, et al.. (2022). MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. Cancers. 14(10). 2563–2563. 9 indexed citations

16.

Zerdan, Maroun Bou & Hazem Assi. (2021). Oligodendroglioma: A Review of Management and Pathways. Frontiers in Molecular Neuroscience. 14. 722396–722396. 15 indexed citations

17.

Zerdan, Maroun Bou, et al.. (2020). Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region. Cancer Treatment and Research Communications. 26. 100275–100275. 3 indexed citations

18.

Saad, Fred, Eric Winquist, Scott Berry, et al.. (2016). Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone. Canadian Urological Association Journal. 10(3-4). 102–102. 9 indexed citations

19.

Weber, Jeffrey S., John A. Thompson, Omid Hamid, et al.. (2009). A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma. Clinical Cancer Research. 15(17). 5591–5598. 460 indexed citations

20.

André, Fabrice, Neslihan Cabıoğlu, Hazem Assi, et al.. (2006). Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Annals of Oncology. 17(6). 945–951. 161 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact